

# NIH Public Access

**Author Manuscript**

*Org Lett*. Author manuscript; available in PMC 2009 January 17.

# Published in final edited form as:

*Org Lett*. 2008 January 17; 10(2): 257–259. doi:10.1021/ol702651s.

# **Total Synthesis of (***3R,9R,10R***)-Panaxytriol via Tandem Metathesis and Metallotropic [1,3]-Shift as a Key Step**

# **Eun Jin Cho**† and **Daesung Lee**\*

*Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Chicago, IL 60607*

# **Abstract**



Enyne metathesis is unique for its capacity to carry out multiple bond formation in tandem fashion. Its combined use with metallotropic [1,3]-shift allowed for the development of a novel strategy for the total synthesis of a conjugated 1,3-diyne-containing natural product (*3R,9R,10R*)-panaxytriol.

> The most unique aspect of synthetic chemistry stems from its capacity to create molecules crucial to addressing problems ranging from fundamental science to human health. The practical synthesis<sup>1</sup> of these target molecules is contingent upon the availability of effective synthetic methods, and thus the development of tandem reactions<sup>2</sup> draws great deal of attention as it induces a significant increase in molecular complexity within a given step.

> Recently, we have introduced a metathesis-based tandem reaction sequence, where an enyne ring-closing metathesis is juxtaposed with one or more metallotropic [1,3]-shift followed by another RCM step. $3$  In this communication, we describe a powerful tandem reaction sequence initiated by relay metathesis, 4 which is followed by metallotropic [1,3]-shift and cross metathesis,<sup>5</sup> as a unique and efficient way for the synthesis of a 1,3-diyne-containing natural compound. 6

> (3*R,*9*R,*10*R*)-panaxytriol **1** was isolated as one of the characteristic constituents of *panax ginseng* C. A. Meyer in 1983. 7 It exhibits inhibitory activity against a range of tumor cell types, including human gastric adenocarcinoma (MK-1),8 human breast carcinoma (Breast  $M25$ -SF),<sup>9</sup> and mouse lymphoma (P388D1)<sup>10</sup>. The structure of panaxytriol was established as heptadec-1-ene-4,6-diyne-3,9,10-triol in  $1989$ ,  $^{11}$  and its absolute configuration was

dsunglee@uic.edu. †University of Wisconsin-Madison

Supporting Information **Available** General procedures and characterization data of new compounds. This material is available free of charge via the internet at<http://pubs.acs.org>

determined as  $3R,9R,10R$  by circular dichroism (CD) analysis  $12$  and confirmed by total syntheses.<sup>13</sup>

Our strategy for the synthesis of **1** is outlined in Scheme 1. We envisioned that the main carbon framework of the target molecule could arise from a tandem reaction sequence of relay metathesis, metallotropic [1,3]-shift, and cross metathesis with enediyne **4** in the presence of an excess amount of external alkene **3**. The intricate array of multiply unsaturated functional groups in **4** could be orchestrated by the recently developed regioselective Alder ene reaction of multiyne **5** 14 with terminal alkene **6** followed by alkyne homologation via the Cadiot-Chodkiewicz reaction15 with bromoalkyne **7**.

The eight-step synthesis of endiyne **4** was initiated by the Ru-catalyzed Alder ene reaction of silylated diyne **5** and 1-decene to provide enyne **8** in 81% yield (Scheme 2).16 The required (9*R,* 10*R*)-diol was installed by the Sharpless asymmetric dihydroxylation, <sup>17</sup> which selectively took place on the disubstituted *trans*-double bond of **8** in 95% yield. The resulting diol was then protected as its acetonide by treating with 2,2-dimethoxypropane (cat. PTSA, THF) to give **9** in 98% yield. In turn, **9** was converted to enyne **10** in 93% overall yield through deacetylation (DIBAL-H, THF, −78 °C), desilylation (TBAF, 10 mol % of AcOH, THF), and O-allylation (NaH, allyl bromide, DMF). Addition of a small amount of acetic acid to the reaction in the desilyation minimizes undesired side reactions that lead to extensive decomposition. For the etherification of the subsequent allylic alcohol, we found that preformation of alkoxide increased the extent of the undesired intramolecular addition of the alkoxide to the nearby triple bond. This undesired byproduct could be suppressed by adding sodium hydride to the mixture of the alcohol and allyl bromide. The elongation of enyne **10** to diyne **4** was achieved in 92% yield employing the Cadiot-Chodkiewicz reaction<sup>14</sup> with silylated bromoalkyne **7** followed by desilylation (TBAF, 10 mol % of AcOH, THF).

With the key substrate **4** in hand, we explored the tandem ring-closing metathesis, metallotropic [1,3]-shift, and cross metathesis. When **4** was treated with Grubbs second generation catalyst<sup>18</sup> (Grubbs II, 10 mol %, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C) in the presence of 2.0 equivalent of alkene **3**, the expected product 2 was obtained in 61% yield as a mixture of  $Z/E$ -isomers  $(5:1)^{4a,19}$ together with ruthenium alkylidene **11′** (10%). The isolated complex **11′** could be turned over to **2** upon treatment with **3**, which implies that this complex is a catalytically viable intermediate in the catalytic cycle. The yield of **11′** was increased up to 40% with stoichiometric amount of Grubbs complex. We speculate that the stability (low reactivity) of **11′** is the consequence of the low steric pressure of the alkynyl group and the hydrogen on the carbenic carbon, which ultimately lowers the rate of phosphine dissociation from the ruthenium center (Scheme 3).

To make the synthetic sequence more convergent, the Alder ene reaction was carried out with triyne **12** and 1-decene **6**, providing diyne **13** in 70% yield (Scheme 4).20 Through the standard sequence, **13** was elaborated to **15** via intermediate **14**. Unfortunately, due to the facile formation of the cyclic ether in basic conditions, 21 the desired allyl ether **4** could not be prepared from **15**, which, however, could be converted to the corresponding allyl silyl ether **17** under less basic conditions. Upon isolation, **17** was directly subjected to the metathesis conditions without purification due to its instability, yielding **2** in 40% overall yield. 22

The completion of total synthesis of (3*R,*9*R,*10*R*)-panaxytriol **1** was achieved in 6 steps from **2** as shown in Scheme 5. Removal of the acyl group of **2** (*cis* : *trans* = 5:1) with DIBAL-H afforded allylic alcohol **18**, which was converted to the required hydroxyl group at C3 through epoxidation followed by ring opening reaction. *Trans*-**18** was founded to react much faster than the corresponding *cis*- isomer in the Sharpless asymmetric epoxidation (SAE) 23 leading to the formation of a 2.8:1 mixture of epoxide **19** with mostly recovered *cis*-**18**. To exploit the faster SAE reaction of *trans*-**18**, the C2–C3 double bond of **18** was isomerized with iodine,

24 resulting in a 1.6:1 ratio of *trans*:*cis* isomers. The Sharpless asymmetric epoxidation of this mixture provided a 8.8:1 mixture of diasteromers **19** in 55% yield together with 15% of unreacted *cis*-**18**. The conversion of the primary alcohol to the corresponding iodoepoxide followed by its reductive ring opening with Zn dust  $^{25}$  gave the (3*R*)-secondary allylic alcohol. Finally, deprotection of the acetonide provided (3*R*,9*R*,10*R*)-panaxytriol **1** the spectroscopic data of which are identical to those reported for natural **1**.

In conclusion, we have developed a novel strategy for a total synthesis of (3*R*,9*R*,10*R*) panaxytriol (**1)** based on the tandem sequence of relay metathesis–metallotropic [1,3]-shift– cross metathesis. This powerful multiple bond-forming reaction allowed an efficient synthesis of the target molecule in 15 steps with 15% overall yield, highlighting its utility for the synthesis of natural products with highly unsaturated carbon skeletons.

## **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

#### **Acknowledgment**

We thank NIH (CA106673) for financial support of this work as well as the NSF and NIH for NMR and Mass Spectrometry instrumentation.

# **References**

- 1. Atom-economy: (a) Trost BM. Science 1991;254:1471. [PubMed: 1962206] Step-economy: (b) Trost BM. Acc. Chem. Res 2002;35:695. [PubMed: 12234199] (c) Wender PA, Bi FC, Gamber GG, Gosselin F, Hubbard RD, Scanio MJC, Sun R, Williams TJ, Zhang L. Pure Appl. Chem 2002;74:25. (c) Wender PA, Miller BL. Toward the Ideal Synthesis. Organic Synthesis: Theory and Application 2:27–66.
- 2. Ho, T-L. Tandem organic reactions. Wiley; New York: 1992. (b) Tietze LF. Chem. Rev 1996;96:115. [PubMed: 11848746] (c) Wasilke J-C, Obrey SJ, Baker RT, Bazan GC. Chem. Rev 2005;105:1001. [PubMed: 15755083] (d) Nicolaou KC, Edmonds DJ, Bulger PG. Angew. Chem. Int. Ed 2006;45:7134.
- 3. (a) Kim M, Lee D. J. Am. Chem. Soc 2005;127:18024. [PubMed: 16366552] (b) Hansen EC, Lee D. Acc. Chem. Res 2006;39:509. [PubMed: 16906747] For a review of metallotropic [1,3]-shift, see: (c) Lee D, Kim M. Org. Biomol. Chem 2007;5:3418. [PubMed: 17943198]
- 4. (a) Hansen EC, Lee D. Org. Lett 2004;6:2035. [PubMed: 15176812] (b) Hoye TR, Jeffrey CS, Tennakoon MA, Wang J, Zhao H. J. Am. Chem. Soc 2004;126:10210. [PubMed: 15315410]
- 5. A review on cross metathesis, see: Connon SJ, Blechert S. Angew. Chem., Int. Ed 2003;42:1900.
- 6. A review of naturally occurring polyynes, see: Shi Shun ALK, Tykwinski RR. Angew. Chem. Int. Ed 2006;45:1034.
- 7. Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, Taniyama T. Yakugaku Zasshi 1983;103:612. [PubMed: 6655550]
- 8. Saita T, Katano M, Matsunaga H, Kouno I, Fujito H, Mori M. Bio. Pharm. Bull 1995;18:933. [PubMed: 7581246]
- 9. Matsunaga H, Saita T, Naguo F, Mori M, Katano M. Cancer Chemother. Pharmacol 1995;35:291. [PubMed: 7828271]
- 10. Kim JY, Lee KW, Kim SH, Wee JJ, Kim YS, Lee HJ. Planta Med 2002;68:119. [PubMed: 11859460]
- 11. Matsunaga H, Katano M, Yamamoto H, Mori M, Takata K. Chem. Pharm. Bull 1989;37:1279. [PubMed: 2630093]
- 12. Kovayashi M, Mahmund T, Umezome T, Wang W, Murakami N, Kitagawa I. Tetrahedron 1997;53:15691.
- 13. Total Syntheses: (a) Lu W, Zheng G, Cai J. Synlett 1998:737. (b) Lu W, Zheng G, Gao D, Cai J. Tetrahedron 1999;55:7157. (c) Gurjar MK, Kumar VS, Rao BV. Tetrahedron 1999;55:12563. (d) Yadav JS, Maiti A. Tetrahedron 2002;58:4955. (e) Mayer SF, Steinreiber A, Orru RVA, Faber K. J. Org. Chem 2002;67:9115. [PubMed: 12492310] (f) Yun H, Danishefsky SJ. J. Org. Chem

2003;68:4519. [PubMed: 12762760] (g) Yun H, Chou T-C, Dong H, Tian Y, Li Y, Danishefsky SJ. J. Org. Chem 2005;70:10375. [PubMed: 16323847]

- 14. (a) Cho EJ, Lee D. J. Am. Chem. Soc 2007;129:6692. [PubMed: 17488017] For reviews on rutheniumcatalyzed Alder ene reaction, see: (b) Trost BM, Frederiksen MU, Rudd MT. Angew. Chem., Int. Ed 2005;44:6630. (c) Trost BM, Toste FD, Pinkerton AB. Chem. Rev 2001;101:2067. [PubMed: 11710241]
- 15. Marino JP, Nguyen HN. J. Org. Chem 2002;67:6841. [PubMed: 12227823] and Supporting Information  $(SI)$  (b) SI of ref<sup>3a</sup> for a slightly modified reaction protocol.
- 16. The transformation of **5** and **6** to **8** was reported in ref 13a .
- 17. (a) Sharpless KB, Amberg W, Bennani YL, Crispino GA, Hartung J, Jeong K-S, Kwong H-L, Morikawa K, Wang Z-M, Xu D, Zhang X-L. J. Org. Chem 1992;57:2768. (b) Kolb HC, VanNieuwenhze MS, Sharpless KB. Chem. Rev 1994;94:2483.
- 18. Scholl M, Ding S, Lee CW, Grubbs RH. Org. Lett 1999;1:953. [PubMed: 10823227]
- 19. *Z*-preference in cross metathesis of enynes and acrylonitrile, see: (a) Crowe WE, Goldberg DR. J. Am. Chem. Soc 1995;117:5162. (b) Randl S, Gessler S, Wakamatsu H, Blechert S. Synlett 2001:430. (c) Kang B, Kim D.-h. Do Y, Chang S. Org. Lett 2003;5:3041. [PubMed: 12916976] (d) Kang B, Lee JM, Kwak J, Lee YS, Chang S. J. Org. Chem 2004;69:7661. [PubMed: 15497994] (e) Love JA, Morgan JP, Trnka TM, Grubbs RH. Angew. Chem. Int. Ed 2002;41:4035.
- 20. The transformation of **12** and **6** to **13** was reported previously in ref 13a .
- 21. For the addition of alkoxide to an alkyne followed by [3,3]-sigmatropic rearrangement, see: (a) Li X, Ovaska TV. Org. Lett 2007;9:3837. [PubMed: 17713920] (b) Li X, Kyne RE, Ovaska TV. Org. Lett 2006;8:5153. [PubMed: 17048866] (c) Martinez I, Alford PE, Ovaska TV. Org. Lett 2005;7:1133. [PubMed: 15760157]
- 22. To the best of our knowledge, this is the first example of using silyl ether as a relay tether.
- 23. (a) Katsuki T, Sharpless KB. J. Am. Chem. Soc 1980;102:5974. (b) Bellina F, Carpita A, Mannocci L, Rossi R. Eur. J. Org. Chem 2004:2610.
- 24. Giacomelli G, Lardicci L, Saba A. J. C. S. Perkin I 1978:314.
- 25. Bernet B, Vasella A. Helv. Chim. Acta 1979;62:1990.



**Scheme 1.**



**Scheme 2.**



**Scheme 3.**



**Scheme 4.**



